Ji-Sook Park

Title: The Innovations of Ji-Sook Park

Introduction

Ji-Sook Park is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins. With a total of 3 patents to her name, her work has the potential to impact medical treatments and therapies.

Latest Patents

Ji-Sook Park's latest patents include innovative fusion proteins that enhance the in vivo activity of erythropoietin. One of her notable inventions involves a fusion protein where the carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of the β subunit of human chorionic gonadotropin (HCG). This invention aims to improve the efficacy of erythropoietin in therapeutic applications. Another significant patent focuses on a fusion protein that combines a carboxy terminal peptide fragment of thrombopoietin with the carboxy terminal of human erythropoietin. This fusion protein boasts a highly enhanced in vivo half-life due to increased carbohydrate content, while maintaining the inherent activity of erythropoietin and avoiding antigenicity when applied to the human body.

Career Highlights

Throughout her career, Ji-Sook Park has worked with notable companies such as Cheiljedang Corp. and CJ Cheiljedang Corporation. Her experience in these organizations has contributed to her expertise in biotechnology and innovation.

Collaborations

Ji-Sook Park has collaborated with esteemed colleagues, including Dong-Eok Lee and Ki-Wan Kim. These partnerships have fostered a collaborative environment that enhances the development of her innovative ideas.

Conclusion

Ji-Sook Park's contributions to the field of biotechnology through her patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for advancements in medical treatments and therapies.